Publications

Export 7 results:
Auteur [ Title(Desc)] Type Année
Filtres: First Letter Of Title is E and Auteur is Serge Gauthier  [Enlever les filtres]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
Gauthier S, Rountree S, Finn B, LaPlante B, Weber E, Oltersdorf T.  2015.  Effects of the Acetylcholine Release Agent ST101 with Donepezil in Alzheimer's Disease: A Randomized Phase 2 Study.. J Alzheimers Dis. 48(2):473-81.
Florian H, Meier A, Gauthier S, Lipschitz S, Lin Y, Tang Q, Othman AA, Robieson WZ, Gault LM.  2016.  Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.. J Alzheimers Dis. 51(4):1237-47.
Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ et al..  2016.  Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial.. Lancet. 388(10062):2873-2884.
Gauthier S, Schlaefke S.  2014.  Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials.. Clin Interv Aging. 9:2065-77.
Benedet AL, Labbe A, Lemay P, Zimmer ER, Pascoal TA, Leuzy A, Mathotaarachchi S, Mohades S, Shin M, Dionne-Laporte A et al..  2015.  Epistasis analysis links immune cascades and cerebral amyloidosis.. J Neuroinflammation. 12:227.
Gauthier S, Rosa-Neto P, Kass JS.  2016.  Ethical Considerations for the Use of Next-Generation Alzheimer Drugs in Symptomatic and At-Risk Patients.. Continuum (Minneap Minn). 22(2 Dementia):615-8.
Vellas B., Sampaio C., Bateman R., Boxer A., Carrillo MC., Cummings J., Dubois B., Hampel H., Katz R., Khachaturian Z. et al..  2014.  E.U./U.S. CTAD Task Force on Alzheimer's Trial Populations. J Prev Alz Dis. 1:110-116.